Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15108316 | 0.91 | CYP3A4 (0.48) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18531965 | 0.89 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10201902 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11919331 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11919326 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2736292 | 0.82 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11919249 | 0.81 | CYP3A4 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10201693 | 0.81 | CYP3A4 (0.51) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2760193 | 0.81 | CYP3A4 (0.51) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2760075 | 0.80 | CYP3A4 (0.47) | CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049506-B9 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2049506-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2118082-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8486942-B2 | Modulators of pharmacokinetic properties of therapeutics | Gilead Sciencs, Inc. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130123311-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123311-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C9 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.